Study of IDH-mutant brain tumors in Brazil
Part of Brain & nervous system, Cancer clinical trials.
This study is collecting information about people in Brazil who have been diagnosed with a type of brain tumor that has an IDH mutation. It aims to better understand the disease and support future research, without giving new treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years old or older.
- You were diagnosed with a diffuse glioma (a type of brain tumor) in Brazil from 2021 onward.
- Your tumor is confirmed to have an IDH mutation (a specific genetic change).
- Your medical records are available for review.
- If you are under 18, your parent or guardian must agree to your participation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HMPL-306, for people with a type of brain tumor (glioma) that has an IDH1 or IDH2 mutation. The goal is to see if the drug can shrink the tumor or slow its growth.
This study looks at the chemicals and genes in brain tumors called gliomas to find better ways to diagnose and treat them. People with a brain mass that needs surgery may be able to join.
This study analyzes tissue and health-related biological data from people with glioblastoma to learn what’s happening in the tumor. The results may help improve future ways to understand and treat glioblastoma using advanced computer analysis.
This study uses a special type of PET/MRI scan to look for a common genetic change (IDH mutation) in brain tumors (gliomas). The goal is to improve how doctors diagnose and treat these tumors.
This study collects tumor tissue and basic medical information to better understand the genes involved in adult diffuse glioma. It may help future treatments by building a detailed research database and matching patients to study arms.
This study looks at tumor tissue from people with a type of brain tumor called IDH-mutant glioma. The goal is to find better ways to measure how many tumor cells remain after treatment, which could help guide future care.
Hear when a new Diffuse Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.